Turn Therapeutics Inc.
TTRXNasdaq
$9.12
↑ +1.0%Jul 17 close · end-of-day
Price
1Y↑ +30.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$252.8M
Enterprise Value
$247.7M
P/E
—
P/S
—
P/B
41.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$3.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-52.2%
ROIC
-443.1%
Debt / Equity
1.0
Net Cash
$5.1M
Return 1Y
—
Company profile
We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™, enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. Our principal executive offices are located in Westlake Village, CA.
- CEO
- Bradley Burnam
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2
- Headquarters
- California
- Website
- turntherapeutics.com/
Management & directors
- Burnam Bradley EvanChief Executive Officer
- Chaudhary ZuraizSee Remarks
- Ghodadra Neilesh ShaileshChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
TTRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.03↑ +200.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$1.8M | -$5.9M |
| Net income | -$1.8M | -$3.2M |
| Diluted EPS | -$0.07 | -$0.12 |
| Operating cash flow | -$1.4M | -$2.6M |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$672,992.00 | -$384,997.00 | -$1.9M | -$1.2M |
| Net income | -$666,442.00 | -$328,547.00 | -$1.9M | -$970,972.00 |
| Diluted EPS | -$0.03 | -$0.01 | -$0.07 | -$0.03 |
| Operating cash flow | — | -$298,058.00 | — | -$1.6M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
Company news
Jul 11, 2026
Jul 8, 2026
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-28 | Burnam Bradley Evan· Chief Executive Officer | Gift | 300,000 | $0.00 | $0.00 | filing |
| 2026-05-28 | Burnam Bradley Evan· Chief Executive Officer | Gift | 300,000 | $0.00 | $0.00 | filing |
| 2026-05-28 | Burnam Bradley Evan· Chief Executive Officer | Gift | 300,000 | $0.00 | $0.00 | filing |
| 2026-05-28 | Burnam Bradley Evan· Chief Executive Officer | Gift | 300,000 | $0.00 | $0.00 | filing |
| 2026-04-02 | Burnam Bradley Evan· Chief Executive Officer | Gift | 300,000 | $0.00 | $0.00 | filing |
| 2026-04-02 | GOLDEN ARTHUR F | Gift | 300,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | Dewhurst Martin William | Award | 21,882 | $0.00 | $0.00 | filing |
| 2025-12-12 | Chaudhary Zuraiz· See Remarks | Buy | 2,500 | $3.50 | $8,750.00 | filing |
| 2025-11-24 | GOLDEN ARTHUR F | Buy | 9,868 | $3.44 | $33,945.92 | filing |
| 2025-11-21 | GOLDEN ARTHUR F | Buy | 20,532 | $2.87 | $58,926.84 | filing |
| 2025-11-21 | Chaudhary Zuraiz· See Remarks | Buy | 1,000 | $3.29 | $3,290.00 | filing |
| 2025-11-20 | Chaudhary Zuraiz· See Remarks | Buy | 1,450 | $2.61 | $3,784.50 | filing |
| 2025-11-17 | Chaudhary Zuraiz· See Remarks | Buy | 2,500 | $3.62 | $9,050.00 | filing |
| 2025-10-23 | GOLDEN ARTHUR F | Buy | 20,202 | $4.95 | $99,999.90 | filing |
| 2025-10-23 | Chesed Abraham | Buy | 14,286 | $4.60 | $65,715.60 | filing |
| 2025-10-23 | Chaudhary Zuraiz· See Remarks | Buy | 5,050 | $4.95 | $24,997.50 | filing |
| 2025-10-08 | Ghodadra Neilesh Shailesh· Chief Medical Officer | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-10-08 | Kester Kent Edward | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-10-08 | GOLDEN ARTHUR F | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-10-08 | Gengos Andrew | Award | 10,000 | $0.00 | $0.00 | filing |
Latest 20 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.